Intestinal anti-inflammatory effects of outer membrane vesicles from Escherichia coli Nissle 1917 in DSS-experimental colitis in mice

Frontiers in Microbiology

Volumn 8, Issue JUL, 2017, Pages

  Fábrega, María José ^a,b   Rodríguez Nogales, Alba ^c   Garrido Mesa, José ^c   Algieri, Francesca ^c   Badía, Josefa ^a,b   Giménez, Rosa ^a,b   Gálvez, Julio ^c   Baldomà, Laura ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Institut de Recerca Sant Joan de Deu   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

DSS experimental colitis; Escherichia coli Nissle 1917; Immune modulation; Mouse model; Outer membrane vesicles; Probiotic

Indexed keywords

DEXTRAN SULFATE;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; EXPERIMENTAL COLITIS; GEL ELECTROPHORESIS; GENE EXPRESSION; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; TRANSMISSION ELECTRON MICROSCOPY; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 85023753029     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2017.01274     Document Type: Article

References (69)

1. Aguilera, L., Toloza, L., Giménez, R., Odena, A., Oliveira, E., Aguilar, J., et al. (2014). Proteomic analysis of outer membrane vesicles from the probiotic strain Escherichia coli Nissle 1917. Proteomics 14, 222-229. doi: 10.1002/pmic.201300328
2. Algieri, F., Rodriguez-Nogales, A., Garrido-Mesa, N., Zorrilla, P., Burkard, N., Pischel, I., et al. (2014). Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis. J. Crohns Colitis 8, 775-788. doi: 10.1016/j.crohns.2013.12.012
3. Alvarez, C.-S., Badia, J., Bosch, M., Giménez, R., and Baldomà, L. (2016). Outer membrane vesicles and soluble factors released by probiotic Escherichia coli Nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. Front. Microbiol. 7:1981. doi: 10.3389/fmicb.2016.01981
4. Arribas, B., Rodríguez-Cabezas, M. E., Camuesco, D., Comalada, M., Bailón, E., Utrilla, P., et al. (2009). A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br. J. Pharmacol. 157, 1024-1033. doi: 10.1111/j.1476-5381.2009.00270.x
5. Becker, C., Neurath, M. F., and Wirtz, S. (2015). The intestinal microbiota in inflammatory bowel disease. ILAR J. 56, 192-204. doi: 10.1093/ilar/ilv030
6. Bellaguarda, E., and Chang, E. B. (2015). IBD and the gut microbiota-from bench to personalized medicine. Curr. Gastroenterol. Rep. 17, 15. doi: 10.1007/s11894-015-0439-z
7. Bleich, A., Sundberg, J. P., Smoczek, A., von Wasielewski, R., de Buhr, M. F., Janus, L. M., et al. (2008). Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. Int. J. Exp. Pathol. 89, 45-54. doi: 10.1111/j.1365-2613.2007.00560.x
8. Buda, A., Jepson, M. A., and Pignatelli, M. (2012). Regulatory function of trefoil peptides (TFF) on intestinal cell junctional complexes. Cell Commun. Adhes. 19, 63-68. doi: 10.3109/15419061.2012.748326
9. Camuesco, D., Comalada, M., Rodríguez-Cabezas, M. E., Nieto, A., Lorente, M. D., Concha, A., et al. (2004). The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br. J. Pharmacol. 143, 908-918. doi: 10.1038/sj.bjp.0705941
10. Camuesco, D., Rodríguez-Cabezas, M. E., Garrido-Mesa, N., Cueto-Sola, M., Bailón, E., Comalada, M., et al. (2012). The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br. J. Pharmacol. 165, 729-740. doi: 10.1111/j.1476-5381.2011.01598.x
11. Cañas, M. A., Giménez, R., Fábrega, M. J., Toloza, L., Baldomà, L., and Badia, J. (2016). Outer membrane vesicles from the probiotic Escherichia coli Nissle 1917 and the commensal ECOR12 enter intestinal epithelial cells via clathrin-dependent endocytosis and elicit differential effects on DNA damage. PLoS ONE 11:e0160374. doi: 10.1371/journal.pone.0160374
12. Claes, I. J. J., De Keersmaecker, S. C. J., Vanderleyden, J., and Lebeer, S. (2011). Lessons from probiotic-host interaction studies in murine models of experimental colitis. Mol. Nutr. Food Res. 55, 1441-1453. doi: 10.1002/mnfr.201100139
13. Cooper, H. S., Murthy, S. N., Shah, R. S., and Sedergran, D. J. (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238-249
14. Dave, M., and Loftus, E. V. (2012). Mucosal healing in inflammatory bowel disease-A true paradigm of success? Gastroenterol. Hepatol. 8, 29-38. doi: 10.1136/gutjnl-2012-302830
15. Ewaschuk, J. B., Diaz, H., Meddings, L., Diederichs, B., Dmytrash, A., Backer, J., et al. (2008). Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G1025-G1034. doi: 10.1152/ajpgi.90227.2008
16. Fábrega, M. J., Aguilera, L., Giménez, R., Varela, E., Cañas, M. A., Antolín, M., et al. (2016). Activation of immune and defense responses in the intestinal mucosa by outer membrane vesicles of commensal and probiotic Escherichia coli strains. Front. Microbiol. 7:705. doi: 10.3389/fmicb.2016.00705
17. Fedorak, R. N. (2010). Probiotics in the management of ulcerative colitis. Gastroenterol. Hepatol. 6, 688-690
18. Floch, M. H., Walker, W. A., Madsen, K., Sanders, M. E., Macfarlane, G. T., Flint, H. J., et al. (2011). Recommendations for probiotic use-2011 update. J. Clin. Gastroenterol. 45, S168-S171. doi: 10.1097/MCG.0b013e318230928b
19. Garg, P., Vijay-Kumar, M., Wang, L., Gewirtz, A. T., Merlin, D., and Sitaraman, S. V. (2009). Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G175-G184. doi: 10.1152/ajpgi.90454.2008
20. Garrido-Mesa, J., Algieri, F., Rodriguez-Nogales, A., Utrilla, M. P., Rodriguez-Cabezas, M. E., Zarzuelo, A., et al. (2015). A new therapeutic association to manage relapsing experimental colitis: doxycycline plus Saccharomyces boulardii. Pharmacol. Res. 97, 48-63. doi: 10.1016/j.phrs.2015.04.005
21. Garrido-Mesa, N., Utrilla, P., Comalada, M., Zorrilla, P., Garrido-Mesa, J., Zarzuelo, A., et al. (2011). The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem. Pharmacol. 82, 1891-1900. doi: 10.1016/j.bcp.2011.09.004
22. Grabig, A., Paclik, D., Guzy, C., Dankof, A., Baumgart, D. C., Erckenbrecht, J., et al. (2006). Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect. Immun. 74, 4075-4082. doi: 10.1128/IAI.01449-05
23. Gronbach, K., Eberle, U., Müller, M., Olschaläger, T. A., Dobrindt, U., Leithäuser, F., et al. (2010). Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. Infect. Immun. 78, 3036-3046. doi: 10.1128/IAI.00218-10
24. Guzy, C., Paclik, D., Schirbel, A., Sonnenborn, U., Wiedenmann, B., and Sturm, A. (2008). The probiotic Escherichia coli strain Nissle 1917 induces T cell apoptosis via caspase-and FasL-dependent pathways. Int. Immunol. 20, 829-840. doi: 10.1093/intimm/dxn041
25. Hering, N. A., Richter, J. F., Fromm, A., Wieser, A., Hartmann, S., Günzel, D., et al. (2014). TcpC protein from E. coli Nissle improves epithelial barrier function involving PKCζ and ERK1/2 signaling in HT-29/B6 cells. Mucosal Immunol. 7, 369-378. doi: 10.1038/mi.2013.55
26. Hou, Y. C., Wu, J. M., Wang, M. Y., Wu, M. H., Chen, K. Y., Yeh, S. L., et al. (2014). Glutamine supplementation attenuates expressions of adhesion molecules and chemokine receptors on T cells in a murine model of acute colitis. Mediators Inflamm. 2014:837107. doi: 10.1155/2014/837107
27. Jia, W., Li, H., Zhao, L., and Nicholson, J. K. (2008). Gut microbiota: a potential new territory for drug targeting. Nat. Rev. Drug Discov. 7, 123-129. doi: 10.1038/nrd2505
28. Jiminez, J. A., Uwiera, T. C., Douglas Inglis, G., and Uwiera, R. R. E. (2015). Animal models to study acute and chronic intestinal inflammation in mammals. Gut Pathog. 7, 29. doi: 10.1186/s13099-015-0076-y
29. Kang, C. S., Ban, M., Choi, E. J., Moon, H. G., Jeon, J. S., Kim, D. K., et al. (2013). Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS ONE 8:e76520. doi: 10.1371/journal.pone.0076520
30. Kaparakis-Liaskos, M., and Ferrero, R. L. (2015). Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 15, 375-387. doi: 10.1038/nri3837
31. Ko, J. K., and Auyeung, K. K. (2014). Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr. Pharm. Des. 20, 1082-1096. doi: 10.2174/13816128113199990416
32. Kolios, G., Valatas, V., and Ward, S. G. (2004). Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113, 427-437. doi: 10.1111/j.1365-2567.2004.01984.x
33. Kruis, W., Fric, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kašcák, M., et al. (2004). Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623. doi: 10.1136/gut.2003.037747
34. Ledoux, D., Labombardi, V. J., and Karter, D. (2006). Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int. J. STD AIDS 17, 280-282. doi: 10.1258/095646206776253507
35. Lin, N., Xu, L. F., and Sun, M. (2013). The protective effect of trefoil factor 3 on the intestinal tight junction barrier is mediated by toll-like receptor 2 via a PI3K/Akt dependent mechanism. Biochem. Biophys. Res. Commun. 440, 143-149. doi: 10.1016/j.bbrc.2013.09.049
36. Xlosurdo, G., Iannone, A., Contaldo, A., Ierardi, E., Di Leo, A., and Principi, M. (2015). Escherichia coli Nissle 1917 in ulcerative colitis treatment: systematic review and meta-analysis. J. Gastrointestin. Liver Dis. 24, 499-505. doi: 10.15403/jgld.2014.1121.244.ecn
37. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275
38. Lozano-Pérez, A. A., Ortiz-cullera, V., Zorrilla, P., Rodriguez-Cabezas, M. E., and Cenis, J. L. (2014). Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats. Int. J. Nanomed. 9, 4507-4520. doi: 10.2147/IJN.S68526
39. Mähler, M., Bristol, I. J., Leiter, E. H., Workman, A. E., Birkenmeier, E. H., Elson, C. O., et al. (1998). Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am. J. Physiol. 274, G544-G551
40. Manichanh, C., Borruel, N., Casellas, F., and Guarner, F. (2012). The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599-608. doi: 10.1038/nrgastro.2012.152
41. Martín, R., Miquel, S., Chain, F., Natividad, J. M., Jury, J., Lu, J., et al. (2015). Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol. 15:67. doi: 10.1186/s12866-015-0400-1
42. Neurath, M. F. (2014). Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329-342. doi: 10.1038/nri3661
43. Nighot, P. K., Al-Sadi, R., Rawat, M., Guo, S., Watterson, D. M., and Ma, T. Y. (2015). Matrix Metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G988-G997. doi: 10.1152/ajpgi.00256.2015
44. Olier, M., Marcq, I., Salvador-Cartier, C., Secher, T., Dobrindt, U., Boury, M., et al. (2012). Genotoxicity of Escherichia coli Nissle 1917 strain cannot be dissociated from its probiotic activity. Gut Microbes 3, 501-509. doi: 10.4161/gmic.21737
45. Olsen, I., and Amano, A. (2015). Outer membrane vesicles-offensive weapons or good samaritans? J. Oral Microbiol. 7:27468. doi: 10.3402/jom.v7.27468
46. Ott, S. J., Musfeldt, M., Wenderoth, D. F., Hampe, J., Brant, O., Fölsch, U. R., et al. (2004). Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53, 685-693. doi: 10.1136/gut.2003.025403
47. Palatka, K., Serfozo, Z., Veréb, Z., Hargitay, Z., Lontay, B., Erdodi, F., et al. (2005). Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease. Scand. J. Gastroenterol. 40, 670-680. doi: 10.1080/00365520510015539
48. Pandurangan, A. K., Ismail, S., Saadatdoust, Z., and Esa, N. M. (2015). Allicin alleviates dextran sodium sulfate-(DSS-) induced ulcerative colitis in BALB/c mice. Oxid. Med. Cell. Longev. 2015:605208. doi: 10.1155/2015/605208
49. Podolsky, D. K., Gerken, G., Eyking, A., and Cario, E. (2009). Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 137, 209-220. doi: 10.1053/j.gastro.2009.03.007
50. Qiao, Y. Q., Cai, C. W., and Ran, Z. H. (2016). Therapeutic modulation of gut microbiota in inflammatory bowel disease: more questions to be answered. J. Dig. Dis. 17, 800-810. doi: 10.1111/1751-2980.12422
51. Rachmilewitz, D., Stamler, J. S., Bachwich, D., Karmeli, F., Ackerman, Z., and Podolsky, D. K. (1995). Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 36, 718-723. doi: 10.1136/gut.36.5.718
52. Ren, G., Sun, A., Deng, C., Zhang, J., Wu, X., Wei, X., et al. (2015). The anti-inflammatory effect and potential mechanism of cardamonin in DSS-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 309, G517-G527. doi: 10.1152/ajpgi.00133.2015
53. Sassone-Corsi, M., Nuccio, S.-P., Liu, H., Hernandez, D., Vu, C. T., Takahashi, A. A., et al. (2016). Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature 540, 280-283. doi: 10.1038/nature20557
54. Scaldaferri, F., Gerardi, V., Mangiola, F., Lopetuso, L. R., Pizzoferrato, M., Petito, V., et al. (2016). Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World J. Gastroenterol. 22, 5505-5511. doi: 10.3748/wjg.v22.i24.5505
55. Schlee, M., Wehkamp, J., Altenhoefer, A., Oelschlaeger, T. A., Stange, E. F., and Fellermann, K. (2007). Induction of human ß-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun. 75, 2399-2407. doi: 10.1128/IAI.01563-06
56. Senol, A., Isler, M., Sutcu, R., Akin, M., Cakir, E., Ceyhan, B. M., et al. (2015). Kefir treatment ameliorates dextran sulfate sodium-induced colitis in rats. World J. Gastroenterol. 21, 13020-13029. doi: 10.3748/wjg.v21.i46.13020
57. Shanahan, F. (2011). The colonic microflora and probiotic therapy in health and disease. Curr. Opin. Gastroenterol. 27, 61-65. doi: 10.1097/MOG.0b013e328340076f
58. Shen, Y., Torchia, M. L. G., Lawson, G. W., Karp, C. L., Ashwell, J. D., and Mazmanian, S. K. (2012). Outer membrane vesicles of a human commensal mediate immune regulation and disease protection. Cell Host Microbe 12, 509-520. doi: 10.1016/j.chom.2012.08.004
59. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., et al. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U.S.A. 105, 16731-16736. doi: 10.1073/pnas.0804812105
60. Souza, B. M., Preisser, T. M., Pereira, V. B., Zurita-Turk, M., de Castro, C. P., da Cunha, V. P., et al. (2016). Lactococcus lactis carrying the pValac eukaryotic expression vector coding for IL-4 reduces chemically-induced intestinal inflammation by increasing the levels of IL-10-producing regulatory cells. Microb. Cell Fact. 15, 150. doi: 10.1186/s12934-016-0548-x
61. Sturm, A., Rilling, K., Baumgart, D. C., Gargas, K., Abou-Ghazalé, T., Raupach, B., et al. (2005). Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling. Infect. Immun. 73, 1452-1465. doi: 10.1128/IAI.73.3.1452-1465.2005
62. Trebichavsky, I., Splichal, I., Rada, V., and Splichalova, A. (2010). Modulation of natural immunity in the gut by Escherichia coli strain Nissle 1917. Nutr. Rev. 68, 459-464. doi: 10.1111/j.1753-4887.2010.00305.x
63. Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., et al. (2007). Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2:e1308. doi: 10.1371/journal.pone.0001308
64. Utrilla, M. P., Peinado, M. J., Ruiz, R., Rodriguez-Nogales, A., Algieri, F., Rodriguez-Cabezas, M. E., et al. (2015). Pea (Pisum sativum L.) seed albumin extracts show anti-inflammatory effect in the DSS model of mouse colitis. Mol. Nutr. Food Res. 59, 807-819. doi: 10.1002/mnfr.201400630
65. Wang, D., and DuBois, R. N. (2010). The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 9, 781-788. doi: 10.1038/onc.2009.421
66. Wasilewski, A., Zielinska, M., Storr, M., and Fichna, J. (2015). Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease. Inflamm. Bowel Dis. 21, 1674-1682. doi: 10.1097/MIB.0000000000000364
67. Xu, X.-R., Liu, C.-Q., Feng, B.-S., and Liu, Z.-J. (2014). Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 20, 3255-3264. doi: 10.3748/wjg.v20.i12.3255
68. Zhang, Y.-Z., and Li, Y.-Y. (2014). Inflammatory bowel disease: pathogenesis. World J. Gastroenterol. 20, 91-99. doi: 10.3748/wjg.v20.i1.91
69. Zyrek, A. A., Cichon, C., Helms, S., Enders, C., Sonnenborn, U., and Schmidt, M. A. (2007). Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 9, 804-816. doi: 10.1111/j.1462-5822.2006.00836.x